GLP-1 Weight-Loss Drugs Show Potential to Slow Cancer Spread in Real-World Study
A Cleveland Clinic retrospective study involving more than 12,000 patients suggests GLP-1 weight‑loss drugs (e.g., semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide, pramlintide) may slow progression to advanced disease for several obesity‑related cancers (lung, breast, colorectal, liver), compared with DPP‑4 inhibitors. In four solid tumors, GLP‑1 users showed notably lower progression to stage 4 (up to 50% in non‑small cell lung cancer, 43% breast, 31% colorectal, 38% liver); prostate, pancreatic, and kidney cancers showed non‑significant trends. Tumors with higher GLP‑1 receptor expression also correlated with better survival. The study is not peer‑reviewed and cannot prove causation; randomized trials are needed to confirm mechanisms and effects.
